• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Response to: Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debate.

作者信息

Wang Yimin, Han Hedong, Zhang Fang, Lv Tangfeng, Zhan Ping, Ye Mingxiang, Song Yong, Liu Hongbing

机构信息

Department of Respiratory Medicine, Jinling Hospital, Nanjing Medical University, Nanjing, China.

Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.

出版信息

Br J Cancer. 2022 Nov;127(8):1383-1384. doi: 10.1038/s41416-022-01930-3. Epub 2022 Sep 5.

DOI:10.1038/s41416-022-01930-3
PMID:36064586
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9553918/
Abstract
摘要

相似文献

1
Response to: Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debate.回复：确定高程序性死亡配体1（PD-L1）表达的晚期非小细胞肺癌的最佳一线治疗方案：一个存在争议的问题。
Br J Cancer. 2022 Nov;127(8):1383-1384. doi: 10.1038/s41416-022-01930-3. Epub 2022 Sep 5.
2
Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debate.确定高程序性死亡配体1（PD-L1）表达的晚期非小细胞肺癌的最佳一线治疗方案：一个存在争议的问题。
Br J Cancer. 2022 Nov;127(8):1381-1382. doi: 10.1038/s41416-022-01929-w. Epub 2022 Sep 5.
3
[Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].非小细胞肺癌中PD-1与PD-L1表达及表皮生长因子受体突变的相关性研究
Zhongguo Fei Ai Za Zhi. 2021 Sep 20;24(9):623-631. doi: 10.3779/j.issn.1009-3419.2021.102.31. Epub 2021 Aug 30.
4
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.采用靶向下一代测序技术对非小细胞肺癌患者进行分析，明确了对抗程序性细胞死亡蛋白 1（PD-1）和抗程序性死亡配体 1（PD-L1）阻断治疗的反应的分子决定因素。
J Clin Oncol. 2018 Mar 1;36(7):633-641. doi: 10.1200/JCO.2017.75.3384. Epub 2018 Jan 16.
5
Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?非小细胞肺癌中PD-1/PD-L1阻断疗法的生物标志物：PD-L1表达是患者选择的良好标志物吗？
Clin Lung Cancer. 2016 Sep;17(5):350-361. doi: 10.1016/j.cllc.2016.03.011. Epub 2016 Apr 6.
6
PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis.PD-1/PD-L1 抑制剂治疗晚期非小细胞肺癌患者的 PD-L1 表达和 EGFR 状态：一项荟萃分析。
Future Oncol. 2019 May;15(14):1667-1678. doi: 10.2217/fon-2018-0639. Epub 2019 May 1.
7
Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.抗 PD-1 抗体在 EGFR 突变和高 PD-L1 表达的 NSCLC 患者中的疗效。
J Cancer Res Clin Oncol. 2021 Jan;147(1):245-251. doi: 10.1007/s00432-020-03329-0. Epub 2020 Jul 23.
8
[Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or 
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].[晚期非小细胞肺癌且PD-L1高表达患者对免疫检查点抑制剂单药治疗或联合化疗反应的评估]
Zhongguo Fei Ai Za Zhi. 2021 Mar 20;24(3):161-166. doi: 10.3779/j.issn.1009-3419.2021.103.02.
9
Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non-small-cell lung cancer characterizes the features of response to PD-1 blockade plus chemotherapy.多指标联合成像检测局部晚期或转移性非小细胞肺癌肿瘤免疫微环境标志物，可预测 PD-1 阻断联合化疗的反应特征。
Cancer Commun (Lond). 2022 Dec;42(12):1331-1346. doi: 10.1002/cac2.12383. Epub 2022 Nov 4.
10
Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.利用 22C3 抗程序性死亡配体 1 抗体检测非小细胞肺癌患者细胞学样本中的程序性死亡配体 1 表达。
Cancer Cytopathol. 2018 Apr;126(4):264-274. doi: 10.1002/cncy.21977. Epub 2018 Feb 7.

引用本文的文献

1
C-reactive protein as robust laboratory value associated with prognosis in patients with stage III non-small cell lung cancer (NSCLC) treated with definitive radiochemotherapy.C-反应蛋白作为与接受根治性放化疗的 III 期非小细胞肺癌（NSCLC）患者预后相关的稳健实验室指标。
Sci Rep. 2024 Jun 14;14(1):13765. doi: 10.1038/s41598-024-64302-2.